Unichem Laboratories' revenue increased 9.3% YoY
  • 05 Nov 2026
  • Unichem Laboratories Ltd reported a 1.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 9.3%.
  • Its expenses for the quarter were up by 0.8% QoQ and 9.3% YoY.
  • The net profit decreased 46.4% QoQ and decreased 286.9% YoY.
  • The earnings per share (EPS) of Unichem Laboratories Ltd stood at 3.14 during Q2 FY 2026-27.

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Unichem Laboratories Ltd is a prominent entity in the pharmaceutical industry, primarily engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is known for its strong focus on research and development, which facilitates the introduction of innovative healthcare solutions. Unichem Laboratories has established a robust presence both in the domestic and international markets, catering to a diverse clientele with a range of therapeutic products. Recent endeavors may include strategic partnerships and expansions aimed at enhancing its market footprint; however, specific recent developments are not available in the provided data.

In the second quarter of the fiscal year 2027 (Q2FY27), Unichem Laboratories Ltd reported a total income of ₹655.59 crores. This reflects a 1.1% increase from the ₹648.23 crores recorded in the first quarter of the fiscal year 2027 (Q1FY27). When compared year-over-year with the second quarter of the fiscal year 2026 (Q2FY26), where total income was ₹599.93 crores, there is a notable increase of 9.3%. This upward trajectory in revenue highlights the company’s consistent performance in generating income over both the quarter and year.

The financial data for Q2FY27 shows that Unichem Laboratories Ltd achieved a profit before tax of ₹27.37 crores, a significant decrease of 44.1% from the previous quarter (Q1FY27), where the profit before tax was ₹48.99 crores. On a year-over-year basis, there was a notable turnaround from a loss before tax of ₹10.82 crores in Q2FY26. The tax expense for Q2FY27 was ₹5.15 crores, which is a 31.5% decline from Q1FY27 but a significant increase from ₹1.07 crores in Q2FY26. Consequently, the profit after tax for Q2FY27 stood at ₹22.22 crores, representing a substantial decline of 46.4% from the ₹41.47 crores in Q1FY27, while reflecting an improvement from a loss of ₹11.89 crores in Q2FY26.

Earnings per share (EPS) for Q2FY27 was ₹3.14, which marks a 46.7% decrease from the preceding quarter, Q1FY27, where EPS was ₹5.89. However, compared to Q2FY26, when the EPS was negative at ₹-1.69, there is a significant positive shift. This indicates a recovery in terms of earnings per share over the year. The total expenses for Q2FY27 amounted to ₹603.96 crores, showing a slight increase of 0.8% from Q1FY27's ₹599.24 crores and aligning with the year-over-year increase of 9.3% from Q2FY26's ₹552.49 crores. These figures reflect the company's operational cost dynamics in relation to its income and profitability outcomes for the respective periods.

Unichem Laboratories Ltd announced its Q2 FY 2026-27 results on 5 November, 2026.

Unichem Laboratories Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.

Key highlights of Unichem Laboratories Ltd Q2 FY 2026-27 results include:

  • Revenue: ₹655.59 crore
  • Net Profit: ₹22.22 crore
  • EBITDA: ₹65.57 crore
  • Year-over-Year Growth: 9.3%
  • Quarter-over-Quarter Growth: 1.1%

Unichem Laboratories Ltd reported a net loss of ₹22.22 crore in Q2 FY 2026-27, reflecting a -286.9% year-over-year growth.

Unichem Laboratories Ltd posted a revenue of ₹655.59 crore in Q2 FY 2026-27.